Columbia University

Memorial Sloan Kettering Cancer Center

Andras Varadi

Konstantin Petrukhin

Donald W Landry

Shi-Xian Deng

Patricia C Weber

Gavril W Pasternak

Andrew Wasmuth

Kirsten Alison Rinderspacher

Susruta Majumdar

Boglarka Racz

Rashad Karimov

Peter Bernstein

Gavril Pasternak

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject. The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout

The present invention provides a compound having the structure: wherein R, R, R, R, and Rare each independently H, halogen, CF, C-Calkyl, aryl or heteroaryl; X is N or CR, wherein Ris H, OH, or halogen; A is absent or present, and when present is B has the structure: or a pharmaceutically acceptable salt thereof.

Triazolopyrimidines, their preparation and use

Described herein are compounds of Formulae (I')-(II&#x2032;), compounds of Formulae (I)-(II) and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful for modulating opioid receptor activity. The provided compounds may have both agonistic and antagonistic effect on one or more opioid receptors. Methods of using the compounds for treating or managing pain are also described. 

Mitragynine analogs and uses thereof

Growing community of inventors

New York, NY, United States of America

Andras Varadi